GET DAILY SIGNALSWhy Is Hims & Hers Health (HIMS) Stock Down -4.50% Today?
Key Takeaways
- Hims & Hers Health (HIMS) shares fell roughly 4.50% to $24.83, reversing part of Friday's sharp rally.
- The primary driver was profit-taking after Friday's roughly 8% surge on a branded GLP-1 distribution deal with Eli Lilly.
- Secondary pressure came from positioning ahead of the company's third-quarter earnings report, due after the close today, and elevated short interest near 23%.
- The decline unfolded against a cautious broader market still stabilizing after last week's technology-led selloff.
- Traders are watching the Q3 print, gross-margin trends, and forward guidance as the next catalysts.
- For deeper analysis, explore Price Targets, Earnings, and Forecast data on this ticker.
- To see which automated strategies are leading right now, browse the Trending AI Robots page.
Opening Summary
HIMS — Hims & Hers Health, Inc., a direct-to-consumer telehealth and wellness platform known for sexual health, dermatology, hair-loss, and weight-loss offerings — traded lower in Monday's session. The stock was down roughly 4.50% to $24.83, compared with Friday's closing price of $26.00. The move marks a pullback after shares jumped about 8% on Friday following the announcement of a partnership to distribute Eli Lilly's branded obesity drugs. With third-quarter results due after the bell today, investors appeared to lock in gains and de-risk into the report.
Profit-Taking After the Eli Lilly Deal Rally
The sharpest near-term catalyst for Monday's weakness is a classic market reaction to the prior session's surge. On Friday, HIMS climbed roughly 8% after announcing an agreement to offer Eli Lilly's (LLY) Zepbound and Foundayo on its telehealth platform, complementing an existing relationship with Novo Nordisk (NVO). Analysts characterized the deal as immediately accretive to earnings before interest and taxes, but at materially lower margins than compounded GLP-1s. After such a sharp single-day gain, short-term traders selling into strength is a typical driver of a down session, especially in a high-beta name.
Earnings Caution Ahead of the Q3 Report
A second, closely related driver is positioning ahead of results. HIMS is scheduled to report third-quarter earnings after the close today, with consensus revenue expectations near $893 million. The company has been navigating a strategic shift from personalized compounded GLP-1s toward branded products, a transition that has compressed gross margins in recent quarters. Investors are likely trimming positions into the print, preferring to avoid the outsized post-earnings swings this stock has produced historically. Given the business transition and ongoing regulatory scrutiny in the weight-loss segment, the market is demanding clarity on margin trajectory and forward guidance.
Elevated Short Interest and Sector Momentum
Technical and positioning factors are amplifying the move. Short interest in HIMS has been reported near 23%, a level that historically contributes to sharp two-way volatility in the stock. The shares had already undercut their 200-day moving average during last week's steep selloff, reflecting fading momentum in telehealth and consumer-health names. Monday's decline keeps the stock below key longer-term trend levels, even as Friday's rally offered a temporary reprieve. The price action underscores how quickly sentiment can rotate in a high-beta growth stock.
Market Context and Trading Activity
The pullback is also consistent with a broader market still stabilizing after last week's technology-led decline. Growth-oriented and speculative healthcare names have been particularly sensitive to shifting risk appetite, and HIMS — with its elevated volatility and heavy retail and short interest — tends to move more than the broader indices in both directions. Volume on the move was active relative to a quiet early session, reflecting genuine two-way positioning rather than a thin, low-liquidity drift. The stock's failure to hold Friday's gains into Monday signals that conviction behind the Eli Lilly catalyst remains limited ahead of the earnings event.
What Comes Next for HIMS
The immediate focus is today's third-quarter report and management commentary. Key items investors will parse include revenue growth relative to the roughly $893 million consensus, gross-margin performance following the pivot to branded GLP-1s, subscriber trends, and full-year guidance. Beyond earnings, the trajectory of the weight-loss business — including the execution of the Eli Lilly and Novo Nordisk partnerships and any further regulatory developments on compounded medications — will shape sentiment. Risks include continued margin compression, competitive pressure from larger telehealth and retail entrants, and the potential for outsized moves driven by the stock's elevated short interest.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of automated trading strategies currently delivering standout performance. Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, and only the strongest performers under present market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a range of approaches to explore. Visit the Trending AI Robots page to see which strategies are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
HIMS in +5.63% Uptrend, growing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HIMS advanced for three days, in 240 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
HIMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In 67 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
HIMS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HIMS crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for HIMS entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.719) is normal, around the industry mean (7.271). P/E Ratio (-41.935) is within average values for comparable stocks, (0.479). Projected Growth (PEG Ratio) (2.624) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (2.686) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric
Advertisement